Loading patent…
AssigneeArrowhead Pharmaceuticals, Inc.
InventorsStacey MELQUIST, Steven KANNER, David B. ROZEMA, David L. LEWIS, Lauren J. ALMEIDA, Darren H. WAKEFIELD, Vladimir S. TRUBETSKOY, Tao PEI, Zhen LI, Aaron ALMEIDA
Estimating the term…
RNA interference (RNAi) agents and RNAi agent conjugates for inhibiting the expression of the LPA (apo(a)) gene are described. Pharmaceutical compositions comprising one or more LPA RNAi agents optionally with one or more additional therapeutics are also described. Delivery of the described LPA RNAi agents to liver cells in vivo provides for inhibition of LPA gene expression and treatment of cardiovascular and cardiovascular-related diseases.
An LPA RNA interference (RNAi) agent comprising a sense strand and an antisense strand, wherein said antisense strand comprises the nucleotide sequence of
An LPA RNA interference (RNAi) agent comprising a sense sequence and an antisense sequence, wherein said antisense sequence comprises a nucleotide sequence of nucleotides 1-17, 2-18, 1-19, 2-19, 1-21, 1-23, or 1-26 of any of the antisense sequences of Table 1 or Table 2A.
Dependencies are inferred from the claim text.